Trading Places: What Shifting US and Canada Supplement Regulations Actually Cost

Five hundred and forty-two dollars. That is the annual fee Health Canada proposed for the right to keep one natural health product on the market, per NPN, every year, whether the product moves or not. A brand carrying 150 licences would owe $81,300 before manufacturing a single bottle, or $60,975 after the small-business reduction. The fee is not in force. It has also never been withdrawn.

Hold that number. It measures a shift the trade keeps getting backwards, because nobody here is deregulating anything. Ottawa has deferred an invoice it already wrote and costed. Washington, moving the other way, is assembling pre-market machinery on top of a mechanism that has spent thirty years turning most applicants away. The two markets are swapping seats, and what follows is what that costs a Canadian catalogue.

The bill Ottawa deferred

The 2022 amendments to the Natural Health Products Regulations get discussed as a design problem. Read the costing and they turn into a capital problem. Health Canada’s own impact analysis put the average label redesign at $5,333 per SKU. Roughly 50,000 SKUs are affected, held by slightly more than 4,000 licence holders, and the department totalled the sector’s bill at $158.7 million in present value over fifteen years.

Industry never accepted those numbers. One in five brands told the Canadian Health Food Association they were seriously considering leaving the Canadian market over regulatory cost. That is not the answer you get to $17,550 spread across fifteen years, which is what the department calculated the average small business would pay. Someone’s arithmetic is wrong, and the unresolved gap between the two is the real reason the date keeps sliding.

Slide it has. A ministerial exemption order signed March 7, 2025 lifted newly licensed products out of their June 2025 obligation and swept the whole catalogue to June 21, 2028. Health Canada has since signalled a further extension, with revised amendments now targeted for Canada Gazette, Part I in spring 2027. Six years after the rules were written, no brand in this country can tell a packaging supplier when to book press time.

The fee file is where the real money sits

Labelling is the headline. Cost recovery is the balance sheet. The revised March 2024 schedule proposed $542 annually per NPN for the right to sell, plus annual site fees of $20,035 for importation, $23,071 for non-sterile manufacturing and $7,650 for packaging. Pre-market evaluation ran from $1,124 for a Class I submission to $58,332 for a Class III novel.

Read the importation line again. Twenty thousand a year, per site, simply to be the party bringing product across the border. That fee was drafted for a world without counter-tariffs. It now queues behind them. Since September 8, 2026, Canada has applied surtaxes of 15, 25 and 50 per cent across $27.6 billion of US imports, with personal care in the top band. Anyone distributing American lines is looking at a tariffed cost base, a fee regime idling offstage, and a labelling deadline nobody will put in writing.

Final fees must clear Canada Gazette, Part II before they bite, which is why the file reads as paused rather than dead. Budgeting on that distinction is budgeting on a technicality.

Washington is building a door it has rarely opened

The FDA named supplements in its 2026 Human Foods Program priorities back in January, promising final new dietary ingredient guidance and a look at modernized oversight. By March it had convened a public meeting on what should even count as a dietary ingredient, with precision fermentation and cell culture forcing the question. A proposed rule scheduled for December would make GRAS notices mandatory for new substances, closing thirty years of self-affirmation.

The track record is the part worth studying before you source another American ingredient. The NDI pathway, closest US analogue to Canadian pre-market review, has taken 1,166 notifications since 1995 and acknowledged 36.5 per cent of them without objection, a rate that sank to 12.6 per cent in fiscal 2017. Two-thirds of the ingredients that bother to knock get an objection letter. That is the filter, in a market Senator Dick Durbin puts at roughly 100,000 products against about 4,000 when DSHEA passed.

Nobody should read this as America turning into Canada. What it is turning into is harder to plan around, because the pressure now arrives through courts and state legislatures rather than the Federal Register. New York’s marketing-based age restriction on weight-loss and muscle-building products survived the Second Circuit in November 2025; CRN took it to the Supreme Court in March. The FTC sued Amare Global in June. None of that surfaces in a rulemaking search before a buyer lists a line.

Why the NPN starts looking like an asset

Canadian operators have spent twenty years treating the Natural Product Number as a tax. On this trajectory it becomes a credential. An NPN file is documented safety, quality and evidence work that US retail diligence teams increasingly ask for and US suppliers often cannot produce. Put plainly: a brand with clean monograph files sits closer to a national vendor review than a competitor with a better label and no dossier behind it.

Retailers get caught on the reverse trade. A longer Canadian runway buys relief on artwork and none at all on language, since claims here are bounded by what the NPN authorizes, and structure-function copy that passes unchallenged in Ohio is not licensed in Ontario. No public figure exists for how much of the Canadian natural health shelf is US-origin. That is a gap this industry should be embarrassed by, though any buyer can measure their own exposure in an afternoon.

Our view

The pause is the worst available outcome for a serious operator. A hard 2028 deadline would have forced the SKU rationalisation this industry has needed for a decade: catalogues costed, the tail cut, the savings redirected into evidence. Instead the cost sits on the books with no date attached, and the discipline never arrives.

Deferral is a subsidy, and it flows to the wrong operators. The heaviest relative burden falls on brands that licensed properly and invested in substantiation. They now compete against companies betting the rules never land at all, and Ottawa has effectively backed the bet.

What IHR is tracking next

Three dates decide how this ends. December 2026, when the FDA’s mandatory GRAS proposal is scheduled. Spring 2027, when Health Canada’s revised labelling amendments are due in Canada Gazette, Part I. And the Supreme Court’s call on the New York case, which tells brands whether marketing-based sales restrictions travel past one state.

IHR will publish the costed read on each within the week it lands, and the fee and deadline figures above are maintained in our regulatory cost tracker, updated whenever the Gazette moves. Until then the arithmetic is the assignment: live NPN count times $542, in front of whoever approves the catalogue, before the next reset order goes in.

Frequently Asked Questions

How much would Health Canada's proposed natural health product fees cost a brand?

The revised March 2024 schedule proposed $542 per NPN annually for the right to sell, $20,035 a year for an importation site licence, and pre-market evaluation from $1,124 to $58,332. Small businesses were offered a first-evaluation waiver and 25 per cent off site and right-to-sell fees. Implementation is paused, not cancelled.

When do the Canadian NHP labelling rules actually take effect?

A March 2025 exemption order aligned every product to June 21, 2028, and Health Canada has since signalled a further extension, with revised amendments targeted for Canada Gazette, Part I in spring 2027. The Product Facts Table requirement has not been withdrawn, only its date.

What is the FDA changing for dietary supplements in 2026?

The FDA committed to final new dietary ingredient guidance in 2026, held a March meeting on modernizing the definition of a dietary ingredient, and has a December 2026 proposed rule requiring GRAS notices for new substances. Congress is separately weighing a federal product listing.

Does holding a Canadian NPN help a brand sell in the United States?

Not legally, since the FDA does not recognize Canadian licences, but commercially it increasingly does. An NPN file documents safety, quality and evidence work that shortens retailer diligence in a market where only about 36 per cent of new dietary ingredient notifications clear without objection.

This is independent editorial analysis from IHR Magazine. Fee figures are Health Canada's proposed amounts and are not in force; timelines were current at publication. Verify NPN status, site licensing, authorized claims and tariff classification with a Canadian regulatory adviser before acting on them.